Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time.

× No keyword cloud information.

10 in total

1. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Authors: Guro Aune; Astrid K Stunes; Solveig Tingulstad; Oyvind Salvesen; Unni Syversen; Sverre H Torp
Journal: Int J Clin Exp Pathol Date: 2011-06-11

2. Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay.

Authors: Jin Zhang; Hongxia Li
Journal: Oncol Lett Date: 2015-03-18 Impact factor: 2.967

3. Fatigue, Mood, and Sleep, During Intraperitoneal Chemotherapy: A Pilot Case Control Study.

Authors: Heather Jim; Anna Barata; Robert Wenham; Paul Jacobsen
Journal: Int J Psychol Res (Medellin) Date: 2013-06

4. Feasibility of an ovarian cancer quality-of-life psychoeducational intervention.

Authors: Shirley Otis-Green; Betty Ferrell; Virginia Sun; Maren Spolum; Robert Morgan; Deborah Macdonald
Journal: J Cancer Educ Date: 2008 Impact factor: 2.037

Review 5. Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed?

Authors: Keiichi Fujiwara; Akira Kurosaki; Kosei Hasegawa
Journal: Curr Oncol Rep Date: 2013-06 Impact factor: 5.075

Review 6. Therapeutic strategies based on polymeric microparticles.

Authors: C Vilos; L A Velasquez
Journal: J Biomed Biotechnol Date: 2012-05-16

7. Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer.

Authors: Sokbom Kang; Tae-Joong Kim; Sang-Soo Seo; Byoung-Gie Kim; Duk-Soo Bae; Sang-Yoon Park
Journal: J Gynecol Oncol Date: 2011-12-05 Impact factor: 4.401

Review 8. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent.

Authors: L De Smet; W Ceelen; J P Remon; C Vervaet
Journal: ScientificWorldJournal Date: 2013-03-25

Review 9. Profile of farletuzumab and its potential in the treatment of solid tumors.

Authors: Seiya Sato; Hiroaki Itamochi
Journal: Onco Targets Ther Date: 2016-03-07 Impact factor: 4.147

Review 10. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.

Authors: Dmitri Pchejetski; Albandri Alfraidi; Keith Sacco; Heba Alshaker; Aun Muhammad; Leonardo Monzon
Journal: J Cancer Res Clin Oncol Date: 2015-11-11 Impact factor: 4.553

10 in total